ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Terminated

Conditions: Attention-Deficit/Hyperactivity Disorder

Interventions: Drug: ABT-089

First Posted Date: 2007-11-06

Last Posted Date: 2011-08-23

Lead Sponsor: Abbott

Target Recruit Count: 283

Registration Number: NCT00554385

Locations: 🇺🇸
Site Ref #/Investigator 8366, Bradenton, Florida, United States
🇺🇸
Site Ref #/Investigator 6808, Jacksonville, Florida, United States
🇺🇸
Site Ref #/Investigator 6824, Overland Park, Kansas, United States

and more 20 locations

Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Placebo
Biological: Adalimumab 80 mg
Biological: Adalimumab 40 mg

First Posted Date: 2007-10-03

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 302

Registration Number: NCT00538902

Locations: 🇨🇳
Site Reference ID/Investigator# 6259, Hefei, Anhui, China
🇨🇳
Site Reference ID/Investigator# 6262, Harbin, China
🇨🇳
Site Reference ID/Investigator# 6333, Shanghai, China

and more 8 locations

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism
Dialysis

Interventions: Drug: Paricalcitol capsules
Drug: Paricalcitol injection

First Posted Date: 2007-10-02

Last Posted Date: 2011-10-25

Lead Sponsor: Abbott

Target Recruit Count: 147

Registration Number: NCT00537979

Locations: 🇲🇽
Site Ref # / Investigator 19391, Jojutla Morelos, Mexico
🇲🇽
Site Ref # / Investigator 19389, Mexico City, Mexico
🇲🇽
Site Ref # / Investigator 19396, Mexico D.F., Mexico

and more 9 locations

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Biological: Humira (adalimumab)

First Posted Date: 2007-08-08

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 203

Registration Number: NCT00513370

A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma

Phase 2

Withdrawn

Conditions: Asthma

First Posted Date: 2007-08-08

Last Posted Date: 2007-11-06

Lead Sponsor: Abbott

Target Recruit Count: 272

Registration Number: NCT00512863

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Phase 3

Completed

Conditions: Mixed Dyslipidemia

Interventions: Drug: ABT-335
Drug: rosuvastatin calcium
Drug: simvastatin
Drug: atorvastatin calcium

First Posted Date: 2007-06-26

Last Posted Date: 2012-01-20

Lead Sponsor: Abbott

Target Recruit Count: 310

Registration Number: NCT00491530

Locations: 🇺🇸
Medical Information Specialist, Abbott Park, Illinois, United States

An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)

Phase 3

Completed

Conditions: Ankylosing Spondylitis

First Posted Date: 2007-05-25

Last Posted Date: 2007-10-10

Lead Sponsor: Abbott

Target Recruit Count: 1250

Registration Number: NCT00478660

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

Phase 3

Completed

Conditions: Hyperlipidemia
Mixed Dyslipidemia

Interventions: Drug: Niacin ER/Simvastatin Tablets
Drug: atorvastatin

First Posted Date: 2007-04-24

Last Posted Date: 2011-06-13

Lead Sponsor: Abbott

Target Recruit Count: 199

Registration Number: NCT00465088

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: adalimumab

First Posted Date: 2007-03-16

Last Posted Date: 2008-08-04

Lead Sponsor: Abbott

Target Recruit Count: 6610

Registration Number: NCT00448383

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Biological: adalimumab
Other: Placebo

First Posted Date: 2007-03-09

Last Posted Date: 2012-02-02

Lead Sponsor: Abbott

Target Recruit Count: 82

Registration Number: NCT00445432

Locations: 🇯🇵
Site Ref # / Investigator 46969, Kagawa, Japan
🇯🇵
Site Ref # / Investigator 46971, Fukuoka, Japan
🇯🇵
Site Ref # / Investigator 46978, Aichi, Japan

and more 26 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy